




The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Keryx Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 28% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	40,004
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	9,767
Liabilities, Non-Current	35
Other Assets	209
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,639
Other Net Income	626
Other Revenues	5,000
Property and Equipment	67
Research and Development	27,012
Selling, General and Administrative Expense	6,737

Output Variable	Value in 1000 USD
Assets	43,488
Liabilities	12,441
Expenses	33,749
Revenues	5,000
Stockholders Equity	31,047
Net Income	-28,123
Comprehensive Net Income	-28,123
BaseVar	47,652
ECR before LimitedLiability	141%
Economic Capital Ratio	262%